SIPV 060923 Lecanemab in Early Alzheimer’s Disease
Geriatric Medicine Journal Club, November 24, 2023
Highlights from AD/PD: Donanemab & iADRS
2023 Notable Articles | New England Journal of Medicine
Donanemab: A Breakthrough for Alzheimer's Disease Oversimplified
Why Enhancing Metabolic Health Could be the Key to Preventing Alzheimer's Disease
An Update on Anti-Amyloid Treatments for Alzheimer's Disease
Reversing Alzheimer's With Coconut Oil | Dr Mary Newport Interview Series 1
Donanemab in early-stage AD: a highlight from AD/PD
Dr Timothy Daly - From Journal Clubs to Letter Writing for ECRs: Why and How
The Newest Alzheimer's Drug: Everything You Need to Know Leqembi! - Dr. McDougall Health
Targeting amyloid beta production for Alzheimer's disease
Dr Yvonne Couch - The Impact of a Paper
Things you NEED to know when starting your own lab
Conversations with Jim Ware - The New England Journal of Medicine
Should amyloid be targeted in Alzheimer's disease?
ADPD 2023 Conference Highlights - Part Two
Cure Alzheimer's Fund and Dr. Rudy Tanzi provide an update on Alzheimer's disease.
New frontiers in Alzheimer's disease research, prevention and treatment
OBD Guest Speaker Reisa Sperling - full version